(Albany, United States) As per DelveInsight’s assessment, globally, the Dyspepsia pipeline constitutes 5+ key companies continuously working towards developing 5+ Dyspepsia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Dyspepsia Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Dyspepsia NDA approvals (if any), and product development activities comprising the technology, Dyspepsia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

To explore more information on the latest breakthroughs in the Dyspepsia pipeline treatment landscape of the report, click here @ Dyspepsia Pipeline Outlook

 

Key Takeaways from the Dyspepsia Pipeline Report

• DelveInsight’s Dyspepsia Pipeline analysis depicts a robust space with 5+ active players working to develop 5+ pipeline treatment therapies.
• The leading Dyspepsia Companies working in the market include RaQualia Pharma and Processa Pharmaceuticals, Astellas Pharma Inc, Naturex SA, Dexa Medica Group, Xian-Janssen Pharmaceuticals Ltd, Novartis, Zeria Pharmaceuticals, Eisai Inc, Daewoong Pharmaceutical Co. Ltd, GlaxoSmithKline, Zeria Pharmaceuticals, Takeda, RedHill Biopharma Ltd, Jiangxi Qingfeng Pharmaceutical Co. Ltd, Bayer, and others
• Promising Dyspepsia Pipeline Therapies in the various stages of development include Mebeverine, GR107719B (Formulation 2), Reference mosapride citrate (GASMOTIN), AMARGOL®, esomeprazole, NISELAT, STW5 (Iberogast®, BAY98-7411), Netazepide, Esomeprazole, Iberogast (STW5-II, BAY98-7410), RHB-105, montelukast, and others.
• On February 2023, Dexa Medica Group announced a study of phase 3 clinical trials for DLBS2411. This is a 2-arm, prospective, double-blind, randomized and placebo-controlled study using DLBS2411 at a dose of 250 mg twice daily (before morning and evening meals), for a 4-week course of therapy, for the treatment of patients with functional dyspepsia (FD), and an additional 8 weeks after end of therapy (Week 12) for follow-up visit.
• On February 2023, Lallemand Health Solutions announced a study of phase 2 & 3 clinical trials for Lacidofil. This study aims at evaluating the efficacy of Lacidofil® STRONG as an adjuvant therapy to a standard 14-day H. pylori eradication treatment among H. pylori-positive participants with non-ulcer dyspepsia.

 

Dyspepsia Overview

Dyspepsia is upper abdominal pain or discomfort that is episodic or persistent and often associated with belching, bloating, heartburn and nausea or vomiting. Dyspepsia can be divided into 2 main categories: “”organic”” and “”functional dyspepsia”” (FD).

 

To explore more information on the latest breakthroughs in the Dyspepsia Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/dyspepsia-pipeline-insight

 

Dyspepsia Emerging Drugs Profile

• RQ-00000010: RaQualia Pharma
• RQ-00201894 : RaQualia Pharma
• PCS12852: Processa Pharmaceuticals

 

Dyspepsia Pipeline Therapeutics Assessment

There are approx. 5+ key companies which are developing the therapies for Dyspepsia. The Dyspepsia companies which have their Dyspepsia drug candidates in the most advanced stage, i.e. phase II include, Processa Pharmaceuticals.

 

Request a sample and discover the recent advances in Dyspepsia Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/dyspepsia-pipeline-insight

 

Dyspepsia Drugs and Companies

• Mebeverine: Abbott
• AMARGOL: Laboratorio Saude Ltda
• Esomeprazole: Odense University Hospital
• NISELAT: Dr. Reddy’s Laboratories Limited
• STW5 (Iberogast®, BAY98-7411): Bayer

 

Dyspepsia Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Dyspepsia Therapeutics Market include-

RaQualia Pharma and Processa Pharmaceuticals, Astellas Pharma Inc, Naturex SA, Dexa Medica Group, Xian-Janssen Pharmaceuticals Ltd, Novartis, Zeria Pharmaceuticals, Eisai Inc, Daewoong Pharmaceutical Co. Ltd, GlaxoSmithKline, Zeria Pharmaceuticals, Takeda, RedHill Biopharma Ltd, Jiangxi Qingfeng Pharmaceutical Co. Ltd, Bayer, and others.

 

Dive deep into rich insights for drugs for Dyspepsia Pipeline, click here for Dyspepsia Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/dyspepsia-pipeline-insight

 

Scope of the Dyspepsia Pipeline Report

• Coverage- Global
• Dyspepsia Companies- RaQualia Pharma and Processa Pharmaceuticals, Astellas Pharma Inc, Naturex SA, Dexa Medica Group, Xian-Janssen Pharmaceuticals Ltd, Novartis, Zeria Pharmaceuticals, Eisai Inc, Daewoong Pharmaceutical Co. Ltd, GlaxoSmithKline, Zeria Pharmaceuticals, Takeda, RedHill Biopharma Ltd, Jiangxi Qingfeng Pharmaceutical Co. Ltd, Bayer, and others.
• Dyspepsia Pipeline Therapies- Mebeverine, GR107719B (Formulation 2), Reference mosapride citrate (GASMOTIN), AMARGOL®, esomeprazole, NISELAT, STW5 (Iberogast®, BAY98-7411), Netazepide, Esomeprazole, Iberogast (STW5-II, BAY98-7410), RHB-105, montelukast, and others.
• Dyspepsia Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Dyspepsia Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/dyspepsia-pipeline-insight

 

Table of Content

1. Introduction
2. Dyspepsia Executive Summary
3. Dyspepsia: Overview
4. Dyspepsia Pipeline Therapeutics
5. Dyspepsia Therapeutic Assessment
6. Dyspepsia– DelveInsight’s Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. Drug Name : Company Name
9. Drug profiles in the detailed report…..
10. Last Stage Products (Phase III)
11. Drug Name : Company Name
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. PCS12852: Processa Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. RQ-00201894 : RaQualia Pharma
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Dyspepsia Key Companies
21. Dyspepsia Key Products
22. Dyspepsia – Unmet Needs
23. Dyspepsia – Market Drivers and Barriers
24. Dyspepsia – Future Perspectives and Conclusion
25. Dyspepsia Analyst Views
26. Dyspepsia Key Companies
27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services